Navigation Links
Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference
Date:10/29/2007

DALLAS, Oct. 29 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that two posters describing significant preclinical studies performed by Access collaborators at two prominent institutes in France, were presented last week at the joint symposium of the American Association for Cancer Research (AACR), National Cancer Institute (NCI) and European Organization for Research and Treatment of Cancer (EORTC) entitled "International Conference Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications One poster provides results of additional studies of the mechanism of ProLindac's anticancer activity, while the second poster demonstrates the potential benefits for cancer therapy of combining ProLindac with other anticancer agents.

"These studies, which are a continuation of work presented at the AACR annual meeting earlier this year, provide further support to our belief that ProLindac has the potential to become an important tool in the fight against cancer" stated David P. Nowotnik, Access' Senior Vice President Research and Development. "One poster shows that the cytotoxicity of ProLindac in a panel of cancer cell lines is greater than that found for either oxaliplatin or cisplatin, while the second poster demonstrates that combinations of ProLindac with certain other anticancer compounds produces cytotoxic effects which are greater than is produced by use of the drugs individually."

In addition, the studies reaffirmed that ProLindac becomes more effective in the lowered pH environment of many tumors by showing that the formation of cancer-killing platinum-DNA adducts increases in tumor cells which are exposed to lower pH conditions. Exposure to ProLindac also resulted in tumor cell cycle arrest at a phase of the cycle where the tumor cell is more susceptible to damage. These effects can lead to programmed death (apoptosis) of the tumor cell. A synergistic effect of ProLind
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
3. Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...   Health 2.0 announces Bernard Tyson , ... Eric Topol , Patrick Soon-Shiong , and Samsung,s ... 8th Annual Fall Conference this coming Sept. 21-24 in ... 2.0 is set to host the very first Wearable Tech ... Consumer Tech & Wearables: Powering Healthy Lifestyles. The ...
(Date:7/28/2014)... July 28, 2014 Anthera Pharmaceuticals, Inc. (NASDAQ: ... for the second quarter ended June 30, 2014. ... 2014 was $7.3 million, compared to $8.3 million for the ... a direct result of a decrease in interest expense in ... six months ended June 30, 2014 was $15.2 million, compared ...
(Date:7/28/2014)... SHORT HILLS, N.J. , July 28, 2014 ... announced a $520,000 settlement of off-label marketing and ... Justice ("DOJ") and Vascular Solutions, Inc. ("VSI").  The ... of various medical devices for endovenous laser ablation ... Stone & Magnanini, a firm with a history ...
Breaking Medicine Technology:Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 2Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 3Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 4Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 5Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 6Anthera Pharmaceuticals Reports 2014 Second Quarter Financial Results and Operational Update 7Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 2Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 3
... initiate Phase 1 trial of AKIi-5 as the first ... ... Aug. 2 Quark Pharmaceuticals, Inc., a,clinical-stage biopharmaceutical company ... today the,presentation of positive results from preclinical efficacy studies ...
... PHILADELPHIA, Aug. 3 GlaxoSmithKline (NYSE:,GSK), one of ... has placed another order to purchase bulk H5N1 ... The company also announced the,start of the first ... pre-pandemic influenza program. HHS Order The ...
Cached Medicine Technology:Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 2Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 3Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF) 4GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 2GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 3GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSK's Candidate Pre-pandemic Flu Vaccine to Start. 4
(Date:7/29/2014)... 29, 2014 PeopleKeys today announced that ... teach students how to train and certify others in ... Behavioral Consultant Trainer , will be taught by PeopleKeys ... Training John Schindell as a live Tele-course over the ... The Certified Behavioral Consultant Trainer course will use a ...
(Date:7/29/2014)... In today’s world, a good night’s sleep has ... sleep apnea (a medical problem where the airway collapses during ... of the rest they need to face their daily challenges. ... 20 million people in the United States alone have sleep ... and of those treated, many cannot tolerate their prescribed medical ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 In its ... offers treatment programs and believes that having family close ... big difference in whether or not the process is ... myths. , “It’s difficult to estimate just how damaging ... Rehabilitation’s CEO Per Wickstrom . “Not only do ...
(Date:7/29/2014)... 2014 Nuanced Media, a leading digital ... HIPAA (Health Insurance Portability and Accountability Act) certified firm. ... storage and transfer of Personal Health Information (PHI). ... Nuanced Media can effectively serve their medical industry clients. ... to offer medical industry specific products such as ...
(Date:7/29/2014)... brides want their bridal dresses and bridal parties to ... sure to provide designs of wedding gowns and bridesmaids ... has recently announced its new collection of gorgeous lace ... come with big savings, up to 61% off. , ... working in the garment industry for several years; they ...
Breaking Medicine News(10 mins):Health News:PeopleKeys Announces New Certified Behavioral Consultant Trainer Course 2Health News:PeopleKeys Announces New Certified Behavioral Consultant Trainer Course 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Latest Best Drug Rehabilitation Blog Post Busts 4 Big Addiction Myths 2Health News:Latest Best Drug Rehabilitation Blog Post Busts 4 Big Addiction Myths 3Health News:Nuanced Media Web Design Agency Now Hipaa Certified 2Health News:LunaDress’ Summer Sale Has Arrived: All Its Gorgeous Lace Wedding Dresses are Affordable Now 2
... Epidemiologists have long warned that, in addition to causing ... person at greater risk for colon cancer. Now, researchers ... explain why. The findings, "Epigenetic Differences in Normal ... Pathways," were published in the March issue of the ...
... HIV-positive patient, one of her first questions is whether he ... response is about dead relatives or friends. "We talk about ... experience will be very different," said the infectious-disease specialist at ... "Yes it,s the same virus and could have the same ...
... Researchers from Boston University School of Medicine (BUSM) and ... breast pain who receive imaging (mammograms, MRIs or ultrasounds) ... testing, but do not gain benefit from these additional ... of General Internal Medicine. Breast pain is ...
... -- Exposure to cocaine, tobacco or marijuana before birth ... tests, according to a new study. Prenatal alcohol ... fetal alcohol syndrome, was associated with lower scores at ... researchers found. The negative associations between intrauterine alcohol ...
... Reporter , TUESDAY, March 6 (HealthDay News) -- New research ... longevity in humans by showing that genetically modified mice live ... a few differences between mice and humans, especially in regard ... genetic tweak, so there,s no way to know if the ...
... -- When faced with stressful situations, older adults who sleep ... a new study finds. The marker, called interleukin-6 (IL-6), ... as cardiovascular disease, diabetes and psychiatric problems. "Our study ... sleep and what poor sleep may be doing to our ...
Cached Medicine News:Health News:Study shows how high-fat diets increase colon cancer risk 2Health News:Federal grant enables HIV testing, treatment in the Augusta area 2Health News:Federal grant enables HIV testing, treatment in the Augusta area 3Health News:Research finds little benefit of breast imaging tests for women with breast pain 2Health News:Fetal Cocaine Exposure May Not Affect Kids' Academics: Study 2Health News:Genetic Tweak Helps Mice Avoid Cancer, Obesity: Study 2Health News:Poor Sleep May Impact Stress Response in Older Adults 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: